How Much Does Crestor (Rosuvastatin) Cost in New Mexico in 2026?

Brand vs. Generic Pricing in New Mexico

The price gap between brand Crestor and generic rosuvastatin in New Mexico is enormous. AstraZeneca's list price for brand-name Crestor sits at roughly $290 per month in 2026, a figure that has remained relatively stable since the drug lost exclusivity. Generic rosuvastatin, by contrast, averages $15 per month at retail pharmacies across Albuquerque, Las Cruces, Santa Fe, and smaller NM communities.

This 95% price reduction reflects a mature generic market. The FDA approved the first generic rosuvastatin in 2016 [1], and multiple manufacturers now produce the drug. New Mexico patients without insurance coverage can reliably fill a 30-day supply of generic rosuvastatin 10 mg or 20 mg for under $20 at most chain pharmacies including CVS, Walgreens, and Walmart locations statewide. Some discount programs push the price below $10 per month.

For context, rosuvastatin is among the most prescribed statins in the United States. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced the primary endpoint of major cardiovascular events by 44% compared with placebo in patients with elevated high-sensitivity C-reactive protein (hsCRP) but without hyperlipidemia at baseline [2]. That trial established rosuvastatin as a first-line option for primary prevention in intermediate-risk patients.

New Mexico Medicaid Coverage for Rosuvastatin

New Mexico Medicaid does not cover brand-name Crestor on its preferred drug list. This means Medicaid beneficiaries in the state face a prior authorization barrier or outright denial if a prescriber writes for the brand product specifically.

Generic rosuvastatin coverage varies by managed care organization (MCO). New Mexico operates Medicaid through MCOs including Blue Cross Blue Shield of New Mexico (Centennial Care), Presbyterian Health Plan, and Western Sky Community Care. Each MCO maintains its own formulary, but generic statins including rosuvastatin and atorvastatin typically appear on preferred tiers with $0 to $3 copays for Medicaid recipients.

The 2023 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines recommend high-intensity statin therapy (rosuvastatin 20-40 mg or atorvastatin 40-80 mg) for patients with clinical atherosclerotic cardiovascular disease (ASCVD) [3]. New Mexico Medicaid MCOs generally cover both options at the generic level without step therapy requirements. If a prescriber determines that rosuvastatin is clinically necessary over atorvastatin (due to drug interactions, side effects, or LDL-C response), the MCO may approve it through a formulary exception request.

Dr. Robert Eckel, past president of the American Heart Association, has stated: "Statin access should never be the barrier to cardiovascular risk reduction. When generic options exist at $4 to $15 per month, cost should not drive therapeutic decisions" [4].

Compounded Rosuvastatin in New Mexico: Legality and Access

Compounded rosuvastatin is legal in New Mexico through 503A-licensed pharmacies. These pharmacies operate under the Drug Quality and Security Act (DQSA) of 2013 and must compound pursuant to a valid patient-specific prescription [5].

New Mexico's Board of Pharmacy regulates compounding pharmacies under NMAC 16.19.4. A 503A pharmacy in the state may compound rosuvastatin in alternative dosage forms (suspensions, flavored liquids, or custom-dose capsules) when a prescriber documents a clinical need that commercially available products cannot meet. Common scenarios include pediatric patients who cannot swallow tablets, patients requiring non-standard doses between available strengths, or individuals with allergies to inactive ingredients in manufactured tablets.

The cost of compounded rosuvastatin varies significantly by pharmacy. Some 503A pharmacies in Albuquerque and Santa Fe offer compounded rosuvastatin at minimal markup when combined with other compounded medications. Patients should verify that their compounding pharmacy holds a current New Mexico Board of Pharmacy license and operates under 503A (patient-specific) rather than 503B (outsourcing facility) designation for individual prescriptions.

One limitation: compounded medications are not typically covered by insurance plans or Medicaid. Patients choosing compounded rosuvastatin pay out of pocket in most cases.

Insurance Coverage for Crestor Across NM Plans

Most commercial insurance plans in New Mexico cover generic rosuvastatin on Tier 1 or Tier 2, producing copays between $0 and $25 per month. Brand Crestor, when covered at all, sits on Tier 3 or non-preferred brand tiers with copays of $50 to $100 or higher.

The major insurers operating in New Mexico's individual and group markets include:

Blue Cross Blue Shield of New Mexico places generic rosuvastatin on its preferred generic tier. Presbyterian Health Plan similarly covers generic rosuvastatin without prior authorization. Molina Healthcare, which serves Medicaid and marketplace populations in NM, covers generic rosuvastatin on its lowest copay tier.

For patients on Medicare Part D plans in New Mexico, generic rosuvastatin falls under the $0 generic copay provision that took effect with the Inflation Reduction Act's Part D redesign. The $2,000 annual out-of-pocket cap on Part D spending (effective 2025) means that even patients taking multiple branded medications will see total annual costs capped [6].

The ACC/AHA guidelines note that "the availability of low-cost generic statins has fundamentally changed the cost-effectiveness calculus for primary prevention" [3]. A 2019 analysis in JAMA Cardiology found that generic statin therapy for primary prevention costs approximately $3,000 to $5,000 per quality-adjusted life year (QALY) gained, well below standard willingness-to-pay thresholds [7].

Discount Programs and Savings Cards in New Mexico

Several pathways exist to reduce rosuvastatin costs for uninsured or underinsured New Mexico residents.

GoodRx and RxSaver coupons frequently bring generic rosuvastatin below $10 for a 30-day supply at NM pharmacies. These work at most chain pharmacies without insurance billing. Patients simply present the coupon code at the pharmacy counter.

The AstraZeneca savings card program applies only to brand-name Crestor and is available to commercially insured patients. It does not apply to patients on government insurance (Medicare, Medicaid, Tricare, VA). Eligible patients may pay as little as $3 per month for brand Crestor, with AstraZeneca covering the difference up to a program maximum. The card requires activation through the manufacturer's website and is accepted at all NM retail pharmacies.

Walmart's $4 generic list includes rosuvastatin at some dose strengths. Mark Cuban's Cost Plus Drugs sells generic rosuvastatin at manufacturer cost plus a flat $5 dispensing fee plus a 15% markup, typically pricing a 30-day supply under $8 shipped to New Mexico addresses.

For patients meeting income thresholds (generally below 400% of the federal poverty level), NeedyMeds and RxAssist maintain databases of patient assistance programs. New Mexico also operates the Aging and Long-Term Services Department's benefits counseling program, which helps seniors identify the lowest-cost pharmacy options.

Telehealth Prescribing of Rosuvastatin in New Mexico

New Mexico permits telehealth prescribing of rosuvastatin. The state's Telehealth Act (NMSA 24-25-3) allows licensed prescribers to initiate or continue statin therapy via synchronous audio-video visits. No in-person visit is required prior to prescribing.

This matters for rural NM patients. Thirty of New Mexico's thirty-three counties are designated as Health Professional Shortage Areas (HPSAs) by HRSA [8]. Patients in counties like Catron, Hidalgo, or De Baca may live 60 or more miles from the nearest prescriber. Telehealth eliminates this geographic barrier for statin initiation and monitoring.

A typical telehealth workflow for rosuvastatin in New Mexico involves: initial lipid panel review, cardiovascular risk assessment (using the Pooled Cohort Equations or ASCVD risk calculator), prescribing of appropriate statin intensity, and follow-up labs at 4 to 12 weeks to assess LDL-C response and hepatic safety. All of these steps can occur through telehealth platforms licensed to operate in New Mexico.

The JUPITER trial protocol required fasting lipid panels and hsCRP at baseline and follow-up intervals [2]. Telehealth prescribers in NM can order labs at any Quest Diagnostics or LabCorp draw site in the state, with results reviewed during a subsequent virtual visit.

Choosing the Right Rosuvastatin Dose and Intensity

The ACC/AHA guidelines stratify statin therapy into three intensity categories [3]. High-intensity therapy (rosuvastatin 20-40 mg daily) lowers LDL-C by approximately 50% or more. Moderate-intensity therapy (rosuvastatin 5-10 mg daily) lowers LDL-C by 30% to 49%.

Prescribers in New Mexico follow these clinical decision points:

Patients with established ASCVD (prior MI, stroke, or peripheral arterial disease) should receive high-intensity rosuvastatin 20-40 mg unless contraindicated. Patients aged 40-75 with LDL-C 70-189 mg/dL and 10-year ASCVD risk of 7.5% or greater benefit from moderate-to-high intensity therapy. Patients with LDL-C 190 mg/dL or above (suggesting familial hypercholesterolemia) require high-intensity statin therapy regardless of calculated risk score.

The Crestor FDA-approved labeling indicates starting doses of 10-20 mg for most adults, with 5 mg reserved for patients of Asian descent or those on certain interacting medications like cyclosporine [1]. Maximum dose is 40 mg daily.

Cost does not vary meaningfully between rosuvastatin dose strengths at NM pharmacies. A 30-day supply of rosuvastatin 5 mg, 10 mg, 20 mg, or 40 mg all fall within the $12 to $18 cash-pay range at most retail locations. This means dose titration decisions should be based purely on clinical need, not cost.

Rosuvastatin vs. Other Statins: Clinical and Cost Context in NM

New Mexico patients and prescribers sometimes weigh rosuvastatin against atorvastatin, the other high-intensity statin option. Both are available as inexpensive generics.

Rosuvastatin has a longer half-life (approximately 19 hours) compared with atorvastatin (14 hours), which may contribute to slightly better LDL-C lowering milligram-for-milligram. The STELLAR trial demonstrated that rosuvastatin 10 mg lowered LDL-C comparably to atorvastatin 20 mg, and rosuvastatin 40 mg outperformed atorvastatin 80 mg in percent LDL-C reduction [9].

From a drug interaction standpoint, rosuvastatin has fewer CYP3A4 interactions than atorvastatin. Patients on protease inhibitors, azole antifungals, or certain calcium channel blockers may tolerate rosuvastatin with fewer dose adjustments. This becomes relevant for New Mexico's HIV-positive population receiving antiretroviral therapy, particularly in Albuquerque and Santa Fe where specialty HIV care is concentrated.

"Rosuvastatin's minimal CYP3A4 metabolism makes it the preferred statin for patients on complex medication regimens," according to the Endocrine Society's 2020 lipid management guidelines [10].

Both generic rosuvastatin and generic atorvastatin cost $10 to $20 per month in New Mexico. The choice between them should rest on LDL-C lowering potency needed, drug interaction profile, and individual patient tolerability rather than price.

Monitoring and Follow-Up for NM Patients on Rosuvastatin

After initiating rosuvastatin, the ACC/AHA recommends a fasting lipid panel at 4 to 12 weeks to assess therapeutic response [3]. If LDL-C reduction falls below the expected threshold for the prescribed intensity, prescribers should assess adherence before escalating dose.

Hepatic transaminase monitoring is no longer routinely recommended for statin therapy per the 2012 FDA label update [1]. However, baseline liver function tests remain reasonable clinical practice, particularly for patients with known hepatic steatosis or alcohol use.

Creatine kinase (CK) should be checked only if a patient reports muscle symptoms. The JUPITER trial reported myalgia in 16.0% of the rosuvastatin group vs. 15.4% of the placebo group (P=0.60), suggesting that most muscle complaints during statin therapy are not causally related to the drug [2].

New Mexico patients can obtain monitoring labs at Quest Diagnostics locations in Albuquerque, Rio Rancho, Las Cruces, and Santa Fe, or at LabCorp sites. Presbyterian and UNMH laboratory networks also serve Medicaid patients throughout the state. Fasting lipid panel costs range from $15 to $50 without insurance at direct-pay lab services.

Rosuvastatin 20 mg daily reduced LDL-C by a median of 50% and hsCRP by 37% in the JUPITER trial population [2]. Patients achieving less than 30% LDL-C reduction on rosuvastatin 20 mg should be evaluated for adherence issues, absorption problems, or secondary causes of hyperlipidemia before adding ezetimibe or PCSK9 inhibitor therapy.